Mirum Pharmaceuticals, Inc.
MIRMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The $6.07B market capitalization puts MIRM squarely in mid-cap range for its industry. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Market Cap
$6.07B
Beta
0.49
P/E (TTM)
—
P/E (Fwd)
-287.10
EPS (TTM)
$-14.08
EPS (Fwd)
$-0.35
ROE
-703.0%
ROA
-6.8%
Cash
$438.3M
Total Debt
$762.9M
Free CF
$76.6M
52W Change
34.7%
Annual Financials
Cash vs Debt
Where MIRM stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, MIRM finished 4.10% below its 150-day moving average ($101.63) and 2.21% above its 200-day moving average ($95.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MIRM overbought or oversold?
At the August 31, 2026 close, MIRM's RSI(14) was 46.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Mirum Pharmaceuticals, Inc. carries $762.9M in total debt against $438.3M in cash reserves — debt is roughly 1.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $76.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -703.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $77.1M (2022) to $521.3M (2025), reflecting a 576% increase over the period.
MIRM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing MIRM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.